Skip to main content
. 2020 Oct 12;9(10):3264. doi: 10.3390/jcm9103264

Figure 2.

Figure 2

Kaplan-Meier analysis of (a) recurrence-free survival and (b) overall survival of patients in the sirolimus (SRL) and tacrolimus (TAC) groups. No significant differences were found between the two groups.